{
    "id": 4153,
    "name": "spinal chordoma",
    "source": "DOID",
    "definition": "A chordoma that derives_from the spine. [url:http\\://www.hopkinsmedicine.org/neurology_neurosurgery/conditions_main/chordoma.html]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:4153",
    "evidence": [
        {
            "id": 6870,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tarceva (erlotinib) and Linsitinib (OSI-906) combination treatment decreased Igf1r and Insr phosphorylation, resulted in a disease control rate of 51% (38/75), and partial response in 7% (5/75) of patients with advanced solid tumors, including a spinal chordoma patient who remained on study for more than 268 weeks (PMID: 26831715).",
            "molecularProfile": {
                "id": 23919,
                "profileName": "IGF1R pos INSR pos"
            },
            "therapy": {
                "id": 4041,
                "therapyName": "Erlotinib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4153,
                "name": "spinal chordoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5935,
                    "pubMedId": 26831715,
                    "title": "Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26831715"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        
    ]
}